PubMed Health⌕ Search

Biomedical subjects

A Perrone

Publications and source records attributed to A Perrone.

At least 73 records · Page 4Linked to original sources
PubMed1988

Lack of effect of nicardipine and diltiazem on glucose- and arginine-induced insulin release in obese subjects.

The metabolic effects of calcium channels blockers have already been studied both in normal and diabetic humans and results were quite controversial, depending on the drug used, the dose administered, and the type of patient. Little information exists on the use of Ca2+ antagonists in obese people, even if these persons are a population risk group for developing diseases in which these drugs may be requested for treatment. Thus, we evaluated, in obese humans, the metabolic effects of two Ca2+ antagonist drugs recently made commercially available to treat diseases such as hypertension and ischemic heart disease: nicardipine and diltiazem. Sixteen obese subjects were submitted to an intravenous glucose tolerance test (0.33 g/kg) (IVGTT) and an arginine test tolerance (30 g in 30 minutes) (ATT) before and after a week of oral treatment with nicardipine (60 mg/day) or diltiazem (360 mg/day). Plasma values of glucose, insulin, and C-peptide during IVGTT, and of glucose, insulin and glucagon during ATT did not show any modification during treatment with either drug. Thus the Ca2+ antagonists, nicardipine and diltiazem, at therapeutic doses in obese subjects do not significantly affect glucose tolerance or insulin and glucagon release.

Arginine↗
PubMed1987

In vitro anti-HBs antibody synthesis from anti-hepatitis B vaccine recipients.

Peripheral blood mononuclear cells (PBMC) from 'responders' recently boosted with hepatitis B vaccine, were studied for synthesis in vitro of antibody to hepatitis B surface antigen (anti-HBs Ab) when stimulated with pokeweed mitogen (PWM) or HBsAg. HBsAg alone can induce an antigen-specific anti-HBs Ab response in vitro; this antibody synthesis is T cell-dependent. In some responders both allogeneic T4+ cells (in absence of PWM or HBsAg) and mixed leucocyte culture supernatants (MLC/SN) (without T cells and antigen) can help responder B cells to produce anti-HBs Ab. Thus, in some immunized subjects, B lymphocytes involved in anti-HBs Ab synthesis are in an advanced phase of differentiation and require only non-antigen specific T cell signals (B cell growth factor or B cell differentiation factor or interleukin 2, etc) to differentiate into antibody-secreting cells. Moreover, the concentration of the antigen necessary to suppress anti-HBs Ab production induced by HBsAg was five times lower than that necessary to suppress antibody production induced by PWM. T cell help for antigen induced anti-HBs Ab could be different from T cell help for the PWM-induced anti-HBs Ab response. Moreover, the finding that the low HBsAg doses inhibiting specific response did not affect the PWM-driven anti-HBs response suggests that antigen-specific T suppressor cells could play a role in this context.

B-Lymphocytes↗
PubMed1985

Blood lipid profile in healthy subjects treated with ticlopidine.

The study was carried out in order to evaluate if Ticlopidine induces lipid metabolism changes. Twenty seven healthy subjects were studied, 14 with placebo and 13 with Ticlopidine treatment (500 mg/day), for 30 days. Total cholesterol, HDL cholesterol, triglycerides, apolipoproteins A and B were evaluated before and after treatment. No significant changes of the blood lipid parameters were observed.

Adult↗
PubMed1985

Platelet hyperfunction in patients with chronic airways obstruction.

Platelet aggregation (PA) and plasma beta-thromboglobulin (beta TG) values were evaluated in 40 patients affected by chronic airway obstruction (CAO). PA and beta TG were significantly higher than those observed in normal subjects. Beta TG plasma levels were inversely correlated with PaO2, directly with PaCO2 and [H+]. Two h after a venesection of 300-400 ml, no change of beta TG and PA was seen in 10 healthy subjects, while a significant increase of beta TG and PA values was observed in 29 patients. The investigation suggests that in patients with CAO in vivo platelet activation is present.

Aged↗
PubMed1983

[Erythrocyte deformability in chronic respiratory insufficiency].

The red blood cell deformability was evaluated in 10 patients suffering from chronic respiratory failure and in 10 normal volunteers. Patients with chronic respiratory failure showed a pH of 7.36 +/- 0.04, a pCO2 of 48.7 +/- 7.3 mmHg and a pO2 of 61.2 +/- 10.2 mmHg and had a decreased red blood cell deformability if compared with normal volunteers (p less than 0.001). The red blood cell deformability of patients suffering from chronic respiratory failure showed a weak correlation with pO2 (r = 0.50, p less than 0.05).

Aged↗
PubMed1982

Influence of ascorbic acid on platelet aggregation in vitro and in vivo.

With the objective of investigating more thoroughly the relationship between ascorbic acid and platelet aggregation (PA) in particular, in vitro and in vivo studies were made whether interferences exist, Scaling amounts of ascorbic acid were added to platelet-rich plasma (PRP) samples to determine the level at which the inhibition of the PA was induce by ADP and arachidonic acid (AA), and endoplatelet malondialdehyde (MDA) concentrations decreased. Changes in PA and MDA were not observed in the PRP control samples Also, in 10 healthy volunteers, an i.v. infusion of ascorbic acid (2 g) produced PA inhibition and a reduction of MDA concentrations.

Ascorbic Acid↗
PubMed1982

The effects of gliclazide on platelet function in patients with diabetes mellitus.

Eighteen diabetic patients with abnormal platelet function were treated for 1 month with gliclazide (80 to 160 mg/day). Platelet aggregation, circulating beta-thromboglobulin levels and platelet malondialdehyde concentrations were significantly reduced after 30 (but not 15) days of treatment. Although fasting and post-prandial glycaemia significantly improved in these patients, similar changes in platelet function were noted in 5 other patients in whom glycaemia did not change. Gliclazide therapy, therefore, brought about an improvement in platelet function and a reduction activation in the thromboxane metabolic pathway, possibly by a direct on the platelets.

Adult↗